The high cost of Soliris (eculizumab) is likely to have catastrophic consequences for people with paroxysmal nocturnal hemoglobinuria…
Articles by Marisa Wexler MS
Treatment with crovalimab, an experimental under-the-skin injection therapy, effectively prevented red blood cell death, reduced the need for blood transfusions,…
Treatment with the experimental complement-blocking therapy omoprubart reduced markers of hemolysis, or blood cell destruction, in people with paroxysmal…
Chugai Pharmaceutical has applied to regulatory authorities in…
NM3086, an experimental therapy for paroxysmal nocturnal hemoglobinuria (PNH) that’s designed to block the alternative complement pathway’s activation, was…
Varicella-zoster virus — which causes chickenpox and shingles — can lead to fatal infections in people with paroxysmal nocturnal…
A bone marrow transplant may be an effective treatment for some people with bone marrow cancer who develop subsequent or…
A woman with paroxysmal nocturnal hemoglobinuria (PNH) that was being well-controlled with Empaveli (pegcetacoplan) saw her symptoms return after…
Most people with paroxysmal nocturnal hemoglobinuria (PNH) who were treated with Soliris (eculizumab) at a hospital in Germany…
Thrombosis — the serious and potentially life-threatening blood clots that can block blood flow — is a common occurrence in…